康華生物(300841.SZ):凍幹人用狂犬病疫苗(人二倍體細胞)獲得藥品再註冊批准通知書
格隆匯2月16日丨康華生物(300841.SZ)公佈,公司於2022年2月15日收到四川省藥品監督管理局下發的《藥品再註冊批准通知書》,藥品名稱為凍幹人用狂犬病疫苗(人二倍體細胞)。
凍幹人用狂犬病疫苗(人二倍體細胞)《藥品再註冊批准通知書》的取得確保了該產品的正常生產和銷售,對公司該產品生產經營資質的穩定延續具有積極意義。公司將嚴格按照相關要求開展藥品生產工作,持續為市場提供高品質的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.